Medeor Therapeutics
PrivateLast Round
Grant
Jan 22, 2018
Total Funding Raised
$75.8M
Company Overview
Medeor Therapeutics operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Grant round in January 2018.
Medeor Therapeutics is a biotechnology company that develops personalized cellular immunotherapies designed to improve outcomes for organ transplant recipients by inducing immune tolerance.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Medeor Therapeutics Comparables
Compare Medeor Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TolerogenixX GmbH | 89% | |
| Taiwan Bio Therapeutics Inc. | 82% | |
| Sangamo Therapeutics Inc | 77% |
For institutional investors. Book with your work email.
Medeor Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 22, 2018 | ||||
| Series B | Nov 27, 2017 |
For institutional investors. Book with your work email.
Medeor Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B |
| WuXi Healthcare Ventures | Series B |
| California Institute for Regenerative Medicine | Grant |
| 6 Dimensions Capital | Series B |
| Sofinnova Investments | Series B |
| Vivo Capital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 7, 2026
Monthly visitors increased 110% MoM.
- Mar 3, 2026
Monthly visitors grew 92% MoM.
For institutional investors. Book with your work email.
Medeor Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Medeor Therapeutics's valuation, stock price, and market status.
Is Medeor Therapeutics a public or private company?
Medeor Therapeutics is a private company.
What is the current stock price of Medeor Therapeutics?
Medeor Therapeutics is a private company, so its shares have no public market price. Caplight tracks Medeor Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Medeor Therapeutics worth (valuation)?
Valuation information for Medeor Therapeutics is not publicly available.
Can I buy Medeor Therapeutics stock?
Medeor Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Medeor Therapeutics's last funding round?
Medeor Therapeutics's most recent funding round was Grant on January 22, 2018.
Who are the main investors in Medeor Therapeutics?
Key investors in Medeor Therapeutics include RA Capital Management.
Will Medeor Therapeutics IPO soon?
No public IPO plans have been announced for Medeor Therapeutics.
How can I track Medeor Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Medeor Therapeutics's shares on secondary markets.